Indications for nuclear strontium dichloride (89Sr) in the treatment of bone metastatic cancer

  Patients with advanced malignant tumors will develop multiple metastases in various parts of the body, among which bone is also a common site of metastasis. Patients with lung cancer, breast cancer, and prostate cancer are most likely to have bone metastases and are accompanied by severe bone pain. If the nuclide bone scan indicates radioactive concentration at the site of multiple bone metastases throughout the body, white blood cell is not less than 3.5*109/L, platelet is not less than 80*109/L, and there is no serious liver and kidney dysfunction, we can choose 89Sr to treat at this time. Radionuclide internal irradiation for bone metastasis cancer can relieve pain, reduce symptoms, improve patients’ survival quality and even prolong life, and this method is easy and safe with few side effects.